Abstract
Recent studies have shown that endogenous metabolites act via aryl hydrocarbon receptor (AhR) signalling pathway in tubulointerstitial fibrosis (TIF) pathogenesis. However, the mechanisms underlying endogenous metabolite-mediated AhR activation are poorly characterised. In this study, we conducted untargeted metabolomics analysis to identify the significantly altered intrarenal metabolites in a mouse model of unilateral ureteral obstruction (UUO). We found that the levels of the metabolite 1-methoxypyrene (MP) and the mRNA expression of AhR and its target genes CYP1A1, CYP1A2, CYP1B1 and COX-2 were progressively increased in the obstructed kidney at Weeks 1, 2 and 3. Furthermore, these changes were positively correlated with progressive TIF in UUO mice. In NRK-52E, RAW 264.7 and NRK-49F cells, MP dose-dependently upregulated the mRNA expression of AhR and its four target genes and the protein expression of nuclear AhR, accompanied by the upregulated protein expression of collagen I, α-SMA and fibronectin, as well as downregulated E-cadherin expression. Consistently, oral administration of MP in mice progressively enhanced AhR activity and upregulated profibrotic protein expression in the kidneys; these effects were partially inhibited by AhR knockdown in MP-treated mice and cell lines. In addition, we screened and identified erythro-guaiacylglycerol-β-ferulic acid ether (GFA), which was isolated from Semen plantaginis, as a new AhR antagonist. GFA significantly attenuated TIF in MP-treated NRK-52E cells and mice by partially antagonising AhR activity. Our results suggest that MP activates AhR signalling, thus mediating TIF through epithelial-mesenchymal transition and macrophage-myofibroblast transition. MP is a crucial metabolite that contributes to TIF via AhR signalling pathway.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Grisaru-Tal S, Itan M, Klion AD, Munitz A. A new dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer. 2020;20:594–607.
Cruz NM, Song X, Czerniecki SM, Gulieva RE, Churchill AJ, Kim YK, et al. Organoid cystogenesis reveals a critical role of microenvironment in human polycystic kidney disease. Nat Mater. 2017;16:1112–9.
Späth MR, Bartram MP, Palacio-Escat N, Hoyer KJR, Debes C, Demir F, et al. The proteome microenvironment determines the protective effect of preconditioning in cisplatin-induced acute kidney injury. Kidney Int. 2019;95:333–49.
Giron-Michel J, Azzi S, Ferrini S, Chouaib S, Camussi G, Eid P, et al. Interleukin-15 is a major regulator of the cell-microenvironment interactions in human renal homeostasis. Cytokine Growth Factor Rev. 2013;24:13–22.
Wang H, Gao M, Li J, Sun J, Wu R, Han D, et al. MMP-9-positive neutrophils are essential for establishing profibrotic microenvironment in the obstructed kidney of UUO mice. Acta Physiol (Oxf). 2019;227:e13317.
Yu XY, Sun Q, Zhang YM, Zou L, Zhao YY. TGF-β/Smad signaling pathway in tubulointerstitial fibrosis [Systematic Review]. Front Pharmacol. 2022;13:860588.
Bhargava V, Singh K, Meena P, Sanyal R. Nephrogenic systemic fibrosis: A frivolous entity. World J Nephrol. 2021;10:29–36.
Mantovani A, Chiara Z. PNPLA3 gene and kidney disease. Explor Med. 2020;1:42–50.
Hansrivijit P, Chen YJ, Lnu K, Trongtorsak A, Puthenpura MM, Thongprayoon C, et al. Prediction of mortality among patients with chronic kidney disease: A systematic review. World J Nephrol. 2021;10:59–75.
Nakamura J, Sato Y, Kitai Y, Wajima S, Yamamoto S, Oguchi A, et al. Myofibroblasts acquire retinoic acid-producing ability during fibroblast-to-myofibroblast transition following kidney injury. Kidney Int. 2019;95:526–39.
Zeisberg M, Maeshima Y, Mosterman B, Kalluri R. Extracellular matrix microenvironment regulates migratory behavior of activated tubular epithelial cells. Am J Pathol. 2002;160:2001–8.
Ruiz-Ortega M, Rayego-Mateos S, Lamas S, Ortiz A, Rodrigues-Diez RR. Targeting the progression of chronic kidney disease. Nat Rev Nephrol. 2020;16:269–88.
Feng YL, Chen DQ, Vaziri ND, Guo Y, Zhao YY. Small molecule inhibitors of epithelial-mesenchymal transition for the treatment of cancer and fibrosis. Med Res Rev. 2020;40:54–78.
Liu BC, Tang TT, Lv LL, Lan HY. Renal tubule injury: a driving force toward chronic kidney disease. Kidney Int. 2018;93:568–79.
Tang PM, Nikolic-Paterson DJ, Lan HY. Macrophages: versatile players in renal inflammation and fibrosis. Nat Rev Nephrol. 2019;15:144–58.
Tang PM, Zhou S, Li CJ, Liao J, Xiao J, Wang QM, et al. The proto-oncogene tyrosine protein kinase Src is essential for macrophage-myofibroblast transition during renal scarring. Kidney Int. 2018;93:173–87.
Zhao X, Kwan JYY, Yip K, Liu PP, Liu FF. Targeting metabolic dysregulation for fibrosis therapy. Nat Rev Drug Disco. 2020;19:57–75.
Miao H, Cao G, Wu XQ, Chen YY, Chen DQ, Chen L, et al. Identification of endogenous 1-aminopyrene as a novel mediator of progressive chronic kidney disease via aryl hydrocarbon receptor activation. Br J Pharmacol. 2020;177:3415–35.
Scott SA, Fu J, Chang PV. Microbial tryptophan metabolites regulate gut barrier function via the aryl hydrocarbon receptor. Proc Natl Acad Sci USA. 2020;117:19376–87.
Zhao H, Chen L, Yang T, Feng YL, Vaziri ND, Liu BL, et al. Aryl hydrocarbon receptor activation mediates kidney disease and renal cell carcinoma. J Transl Med. 2019;17:302.
Rothhammer V, Quintana FJ. The aryl hydrocarbon receptor: an environmental sensor integrating immune responses in health and disease. Nat Rev Immunol. 2019;19:184–97.
Baker JR, Sakoff JA, McCluskey A. The aryl hydrocarbon receptor (AhR) as a breast cancer drug target. Med Res Rev. 2020;40:972–1001.
Xue Z, Li D, Yu W, Zhang Q, Hou X, He Y, et al. Mechanisms and therapeutic prospects of polyphenols as modulators of the aryl hydrocarbon receptor. Food Funct. 2017;8:1414–37.
Murray IA, Patterson AD, Perdew GH. Aryl hydrocarbon receptor ligands in cancer: friend and foe. Nat Rev Cancer. 2014;14:801–14.
Miao H, Wu XQ, Wang YN, Chen DQ, Chen L, Vaziri ND, et al. 1-Hydroxypyrene mediates renal fibrosis through aryl hydrocarbon receptor signalling pathway. Br J Pharmacol. 2022;179:103–24.
Wang M, Chen DQ, Chen L, Cao G, Zhao H, Liu D, et al. Novel inhibitors of the cellular renin-angiotensin system components, poricoic acids, target Smad3 phosphorylation and Wnt/β-catenin pathway against renal fibrosis. Br J Pharmacol. 2018;175:2689–708.
Zhao YY, Cheng XL, Wei F, Bai X, Tan XJ, Lin RC, et al. Intrarenal metabolomic investigation of chronic kidney disease and its TGF-β1 mechanism in induced-adenine rats using UPLC Q-TOF/HSMS/MSE. J Proteome Res. 2013;12:2692–703.
Chen DQ, Cao G, Chen H, Argyopoulos CP, Yu H, Su W, et al. Identification of serum metabolites associating with chronic kidney disease progression and anti-fibrotic effect of 5-methoxytryptophan. Nat Commun. 2019;10:1476.
Chen H, Yang T, Wang MC, Chen DQ, Yang Y, Zhao YY. Novel RAS inhibitor 25-O-methylalisol F attenuates epithelial-to-mesenchymal transition and tubulo-interstitial fibrosis by selectively inhibiting TGF-β-mediated Smad3 phosphorylation. Phytomedicine. 2018;42:207–18.
Bisson WH, Koch DC, O’Donnell EF, Khalil SM, Kerkvliet NI, Tanguay RL, et al. Modeling of the aryl hydrocarbon receptor (AhR) ligand binding domain and its utility in virtual ligand screening to predict new AhR ligands. J Med Chem. 2009;52:5635–41.
Ginalski K. Comparative modeling for protein structure prediction. Curr Opin Struct Biol. 2006;16:172–7.
Zhao YY, Liu J, Cheng XL, Bai X, Lin RC. Urinary metabonomics study on biochemical changes in an experimental model of chronic renal failure by adenine based on UPLC Q-TOF/MS. Clin Chim Acta. 2012;413:642–49.
Zhao YY, Cheng XL, Cui JH, Yan XR, Wei F, Bai X, et al. Effect of ergosta-4,6,8(14),22-tetraen-3-one (ergone) on adenine-induced chronic renal failure rat: a serum metabonomic study based on ultra performance liquid chromatography/high-sensitivity mass spectrometry coupled with MassLynx i-FIT algorithm. Clin Chim Acta. 2012;413:1438–45.
Zhao YY, Tang DD, Chen H, Mao JR, Bai X, Cheng XH, et al. Urinary metabolomics and biomarkers of aristolochic acid nephrotoxicity by UPLC-QTOF/HDMS. Bioanalysis. 2015;7:685–700.
Shinde R, McGaha TL. The aryl hydrocarbon receptor: connecting immunity to the microenvironment. Trends Immunol. 2018;39:1005–20.
Luo LP, Suo P, Ren LL, Liu HJ, Zhang Y, Zhao YY. Shenkang injection and its three anthraquinones ameliorates renal fibrosis by simultaneous targeting IƙB/NF-ƙB and Keap1/Nrf2 signaling pathways. Front Pharmacol. 2021;12:800522.
Yang Y, Wu C. Traditional chinese medicine in ameliorating diabetic kidney disease via modulating gut microbiota. Integr Med Nephrol Androl. 2021;8:8.
Zhou XF, Wang Y, Luo MJ, Zhao TTPL. Tangshen formula attenuates renal fibrosis by downregulating transforming growth factor β1/Smad3 and LncRNA-MEG3 in rats with diabetic kidney disease. Integr Med Nephrol Androl. 2021;8:1.
Zhao H, Xu J, Wang R, Tang W, Kong L, Wang W, et al. Plantaginis Semen polysaccharides ameliorate renal damage through regulating NLRP3 inflammasome in gouty nephropathy rats. Food Funct. 2021;12:2543–53.
Yang F, Shi W, Wang L, Qin N, Wang C, Guo Y, et al. Lipidomics study of the therapeutic mechanism of Plantaginis Semen in potassium oxonate-induced hyperuricemia rat. BMC Complement Med Ther. 2021;21:175.
Tzeng TF, Liu WY, Liou SS, Hong TY, Liu IM. Antioxidant-rich extract from Plantaginis semen ameliorates diabetic retinal injury in a streptozotocin-induced diabetic rat model. Nutrients 2016;8:572.
Ren Z, Yu R, Meng Z, Sun M, Huang Y, Xu T, et al. Spiky titanium dioxide nanoparticles-loaded Plantaginis Semen polysaccharide as an adjuvant to enhance immune responses. Int J Biol Macromol. 2021;191:1096–104.
Sharief Nohammad N, Srinivasulu A, Chittibabu B, Umamaheswara Rao V. Isolation and purification of antibacterial principle from Avicennia marina L in methanol. Int J Pharm Pharm Sci. 2014;7:38–41.
Sawhney H, Gill SS. Renal transplant recipient seizure practical management. World J Nephrol. 2020;9:1–8.
Carta P, Lorenzo DM, Luciano M, Aida L, Caroti L, Cirami L. Malignancies after renal transplantation: A single center retrospective study. J Nephrol Hypertens. 2020;3:1009.
Bacharaki D, Chrysanthopoulou E, Grigoropoulou S, Giannakopoulos P, Simitsis P, Frantzeskaki F, et al. Siblings with coronavirus disease 2019 infection and opposite outcome-the hemodialysis’s better outcome paradox: Two case reports. World J Nephrol. 2021;10:21–8.
Chuengsaman P, Narenpitak S, Sritippayawan S. Efficacy and safety of recombinant human erythropoietin (Hema-Plus(®)) for management of anemia in Thai patients on peritoneal dialysis. World J Nephrol. 2021;10:109–21.
Tamura H. Trends in pediatric nephrotic syndrome. World J Nephrol. 2021;10:88–100.
Chaudhuri O, Cooper-White J, Janmey PA, Mooney DJ, Shenoy VB. Effects of extracellular matrix viscoelasticity on cellular behaviour. Nature. 2020;584:535–46.
Romani P, Brian I, Santinon G, Pocaterra A, Audano M, Pedretti S, et al. Extracellular matrix mechanical cues regulate lipid metabolism through Lipin-1 and SREBP. Nat Cell Biol. 2019;21:338–47.
Li SS, Sun Q, Hua MR, Suo P, Chen JR, Yu XY, et al. Targeting the Wnt/β-catenin signaling pathway as a potential therapeutic strategy in renal tubulointerstitial fibrosis. Front Pharmacol. 2021;12:719880.
Nguyen PT, Dorman LC, Pan S, Vainchtein ID, Han RT, Nakao-Inoue H, et al. Microglial remodeling of the extracellular matrix promotes synapse plasticity. Cell. 2020;182:388–403.e15.
Piperigkou Z, Karamanos NK. Dynamic interplay between mirnas and the extracellular matrix influences the tumor microenvironment. Trends Biochem Sci. 2019;44:1076–88.
Deng M, Lin J, Nowsheen S, Liu T, Zhao Y, Villalta PW, et al. Extracellular matrix stiffness determines DNA repair efficiency and cellular sensitivity to genotoxic agents. Sci Adv. 2020;6:eabb2630.
Merchant ML, Barati MT, Caster DJ, Hata JL, Hobeika L, Coventry S, et al. Proteomic analysis identifies distinct glomerular extracellular matrix in collapsing focal segmental glomerulosclerosis. J Am Soc Nephrol. 2020;31:1883–904.
Mayeux PR, MacMillan-Crow LA. Pharmacological targets in the renal peritubular microenvironment: implications for therapy for sepsis-induced acute kidney injury. Pharmacol Ther. 2012;134:139–55.
Rinschen MM, Saez-Rodriguez J. The tissue proteome in the multi-omic landscape of kidney disease. Nat Rev Nephrol. 2021;17:205–19.
Ngo D, Wen D, Gao Y, Keyes MJ, Drury ER, Katz DH, et al. Circulating testican-2 is a podocyte-derived marker of kidney health. Proc Natl Acad Sci USA. 2020;117:25026–35.
Schunk SJ, Floege J, Fliser D, Speer T. WNT-β-catenin signalling - a versatile player in kidney injury and repair. Nat Rev Nephrol. 2020;17:172–84.
Perry HM, Görldt N, Sung SJ, Huang L, Rudnicka KP, Encarnacion IM, et al. Perivascular CD73+ cells attenuate inflammation and interstitial fibrosis in the kidney microenvironment. Am J Physiol Ren Physiol. 2019;317:F658–F69.
Sallee M, Dou L, Cerini C, Poitevin S, Brunet P, Burtey S. The aryl hydrocarbon receptor-activating effect of uremic toxins from tryptophan metabolism: a new concept to understand cardiovascular complications of chronic kidney disease. Toxins 2014;6:934–49.
Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380–90.
Fang Y, Gong AY, Haller ST, Dworkin LD, Liu Z, Gong R. The ageing kidney: Molecular mechanisms and clinical implications. Ageing Res Rev. 2020;63:101151.
Edeling M, Ragi G, Huang S, Pavenstadt H, Susztak K. Developmental signalling pathways in renal fibrosis: the roles of Notch, Wnt and Hedgehog. Nat Rev Nephrol. 2016;12:426–39.
Rinschen MM, Ivanisevic J, Giera M, Siuzdak G. Identification of bioactive metabolites using activity metabolomics. Nat Rev Mol Cell Biol. 2019;20:353–67.
Hocher B, Adamski J. Metabolomics for clinical use and research in chronic kidney disease. Nat Rev Nephrol. 2017;13:269–84.
Hatanaka N, Yamazaki H, Kizu R, Hayakawa K, Aoki Y, Iwanari M, et al. Induction of cytochrome P450 1B1 in lung, liver and kidney of rats exposed to diesel exhaust. Carcinogenesis. 2001;22:2033–8.
Iwanari M, Nakajima M, Kizu R, Hayakawa K, Yokoi T. Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. Arch Toxicol. 2002;76:287–98.
Wu M, Jiang Y, Liu M, Shang Y, An J. Amino-PAHs activated Nrf2/ARE anti-oxidative defense system and promoted inflammatory responses: the regulation of PI3K/Akt pathway. Toxicol Res (Camb). 2018;7:465–72.
Liu Y, Zhang H, Zhang H, Niu Y, Fu Y, Nie J, et al. Mediation effect of AhR expression between polycyclic aromatic hydrocarbons exposure and oxidative DNA damage among Chinese occupational workers. Environ Pollut. 2018;243:972–77.
Serdar B, Lee D, Dou Z. Biomarkers of exposure to polycyclic aromatic hydrocarbons (PAHs) and DNA damage: a cross-sectional pilot study among roofers in South Florida. BMJ Open. 2012;2:e001318.
Freitas F, Brucker N, Durgante J, Bubols G, Bulcao R, Moro A, et al. Urinary 1-hydroxypyrene is associated with oxidative stress and inflammatory biomarkers in acute myocardial Infarction. Int J Environ Res Public Health. 2016;11:9024–37.
Ciolino HP, Daschner PJ, Wang TT, Yeh GC. Effect of curcumin on the aryl hydrocarbon receptor and cytochrome P450 1A1 in MCF-7 human breast carcinoma cells. Biochem Pharmacol. 1998;56:197–206.
Acknowledgements
This study was supported by the National Natural Science Foundation of China (Nos. 82074002, 81922073, 81872985) and the National Key Research and Development Project of China (No. 2019YFC1709405).
Author information
Authors and Affiliations
Contributions
YYZ designed the study. GC, HM, YNW, DQC, XQW, LC and LZ performed the experiments. YG and YYZ performed the statistical analysis. GC, HM and YYZ prepared the paper. NDV and PL revised the paper. All authors read and approved the final paper.
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Cao, G., Miao, H., Wang, Yn. et al. Intrarenal 1-methoxypyrene, an aryl hydrocarbon receptor agonist, mediates progressive tubulointerstitial fibrosis in mice. Acta Pharmacol Sin 43, 2929–2945 (2022). https://doi.org/10.1038/s41401-022-00914-6
Received:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/s41401-022-00914-6
Keywords
This article is cited by
-
Acteoside-containing caffeic acid is bioactive functional group of antifibrotic effect by suppressing inflammation via inhibiting AHR nuclear translocation in chronic kidney disease
Acta Pharmacologica Sinica (2025)
-
Poria cocos: traditional uses, triterpenoid components and their renoprotective pharmacology
Acta Pharmacologica Sinica (2025)
-
Urinary metabolites associated with the long-term risk for chronic kidney disease incidence and progression in hypertensive patients
Metabolomics (2025)
-
Sirtuin 6 protects against podocyte injury by blocking the renin-angiotensin system by inhibiting the Wnt1/β-catenin pathway
Acta Pharmacologica Sinica (2024)
-
Targeting Lactobacillus johnsonii to reverse chronic kidney disease
Signal Transduction and Targeted Therapy (2024)
